Alteplase has been the mainstay of thrombolytic treatment since the National Institutes of Neurological Disorders and Stroke trial was published in 1995. Over recent years, several trials have investigated alternative thrombolytic agents. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, allowing single intravenous bolus administration without infusion, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor compared to alteplase. Tenecteplase is established as the first-line intravenous thrombolytic drug for myocardial infarction, where it has been shown to achieve comparable reperfusion with reduced risk of systemic bleeding in comparison to alteplase. We review the literature on tenecteplase for the treatment of acute ischemic stroke, with a focus on the major completed and ongoing trials. Overall, tenecteplase shows promise for treatment of acute ischemic stroke, both in populations currently eligible for alteplase and also in groups not currently treated with thrombolysis.
Thrombolytic treatment with the recombinant tissue plasminogen activator (rtPA) alteplase significantly increases the probability of excellent recovery (approximately 10% absolute and 60% relative increase in the likelihood of recovery without significant neurological deficit in the most recent meta-analyses). 6 While there are clear benefits from IV alteplase, [6] [7] [8] clinical anxiety about risks-particularly of symptomatic intracerebral hemorrhage (SICH)-and variation in guidelines lead many patients to not be treated 9, 10 despite evidence of potential benefit from treatment and of poor outcome when not treated 11 A safer agent would potentially change the perceived risk to benefit ratio substantially, and allow a greater proportion of eligible patients to be treated. In stroke, alteplase achieves early recanalization in fewer than 50% of patients, 12 and, only half of those who recanalize do so within 2 h of drug administration. 13 Alteplase recanalizes large artery occlusion (terminal internal carotid artery or proximal middle cerebral artery) within 2 h in fewer than 10% of cases. 12, 14 There is potentially substantial benefit from better IV thrombolytic agents.
Tenecteplase-A promising thrombolytic drug for treatment of stroke
Despite recognition of the limited efficacy of alteplase and availability of thrombolytic agents with potentially superior efficacy, better safety profile, and easier administration schedule, alteplase has remained the sole IV thrombolytic agent for stroke since the NINDS trial in 1995. 15 Clinical trials of desmoteplase, a thrombolytic drug with far greater fibrin specificity than alteplase, focused on late time windows among patients with imaging features thought to signify persistent viable penumbra. [16] [17] [18] These studies failed to demonstrate efficacy, but with hindsight had issues with inconsistent application of imaging selection criteria, and failed to reach their target sample sizes. Tenecteplase, a genetically engineered mutant tPA, was developed to improve recanalization 19 over alteplase through higher affinity binding to fibrin, greater resistance to inactivation by plasminogen activator inhibitor-1(PAI-1), less disruption of hemostasis, and longer free plasma halflife, allowing single IV bolus administration. This has substantial practical advantages over the 1 h infusion of alteplase, 20 particularly as many patients are transferred between and within hospitals for treatments such as endovascular thrombectomy. 21, 22 Tenecteplase is established as the first-line IV thrombolytic drug for myocardial infarction, 23, 24 where it has been shown to achieve comparable reperfusion with reduced systemic hemorrhage in comparison to alteplase. 25, 26 In stroke, data from small phase 2 trials suggest that these pharmacodynamic differences may result in higher recanalization rates without increased hemorrhage rates. [27] [28] [29] Completed trials of tenecteplase for acute ischemic stroke Prior to 2017, six small clinical studies of tenecteplase in acute stroke had been reported 27, [30] [31] [32] including three small RCTs. 27, 28, 30 In two initial dose-finding safety studies, Haley et al. 30 undertook an ascending dose safety RCT that evaluated tenecteplase doses between 0.1 mg/kg and 0.5 mg/kg, and a single center Australian case series described use of the 0.1 mg/kg dose in an extended treatment time window of 3-6 h based on multimodal CT imaging selection. 31 In a subsequent RCT, Haley et al. 32 discontinued recruitment to a higher dose group (0.4 mg/kg) after only 19 subjects on the basis of early safety and efficacy data, but were unable to discriminate between 0.1 mg/kg and 0.25 mg/kg on grounds of either safety or efficacy. The Australian TNK trial 28 reported superiority of tenecteplase 0.1 mg/kg and 0.25 mg/kg over alteplase in 75 patients, in terms of both imagingdefined reperfusion and clinical outcomes, in a selected group of patients with large artery occlusion and favorable brain perfusion patterns defined on computed tomography perfusion (CTP) up to 6 h after stroke onset. The 0.1 mg/kg dose exhibited inferior recanalization and reperfusion compared to 0.25 mg/kg, although both were superior to alteplase. The ATTEST single center RCT compared alteplase with tenecteplase 0.25 mg/kg and gathered imaging data for outcome evaluation and to characterize pathophysiology at baseline, but did not select on imaging criteria. 27 Despite baseline imbalance with more negative prognostic features in the tenecteplase group (a higher proportion of large artery occlusion-75% vs. 61%-and 33% larger ischemic core volume-representing irreversibly damaged tissue), there were trends towards greater earlier major neurological improvement and lower total ICH incidence in the tenecteplase-treated group. In a sub-study, tenecteplase was associated with significantly less disruption of the fibrinolytic system 22 : alteplase caused significant reduction in fibrinogen, prolongation of prothrombin time, increase in PAI-1 activity, and reduction of plasminogen over 24 h, all of which are associated with an increased risk of bleeding. Tenecteplase did not cause change in any of these parameters. Markers of clot lysis efficacy were, however, the same for both agents.
In all of these prior studies, the target population was those eligible for IV thrombolysis, or a sub-group of eligible subjects defined by imaging. TEMPO-1 was a phase 2 dose-escalation safety study of tenecteplase in International Journal of Stroke, 13 (9) an extended time window in a group, with minor stroke, who are largely excluded from current guidelines. 33 Fifty patients with minor stroke (NIHSS 0-5) and intracranial occlusion identified on CTA were treated with tenecteplase in a 12-h window at 0.1 mg/kg (first tier of 25 patients) and 0.25 mg/kg (second tier of 25 patients). Recanalization rates were higher with 0.25 mg/kg dosing (61%) and complete recanalization predicted excellent functional outcome (mRS 0-1) at 90 days (RR 1.65: 95% CI 1.1-2.5, p ¼ 0.026).
In an individual patient data meta-analysis of the three RCTs comparing tenecteplase and alteplase, 27, 28, 30 the tenecteplase 0.25 mg/kg dose (total n ¼ 216) was associated with a shift in distribution of modified Rankin Scale at 90 days in favor of tenecteplase (adjusted OR 1.4, 95% CI 0.5, 4.3) as well as showing a trend towards lower symptomatic intracranial hemorrhage rates (4/108 tenecteplase, 3.7% versus 7/108 alteplase, 6.5%, adjusted OR 0.7, 95% CI 0.2, 2.5). 34 Since 2017, two multicenter RCTs have reported findings, NORTEST and EXTEND-IA TNK. The NORTEST study compared tenecteplase 0.4 mg/kg to alteplase in adults with ischemic stroke eligible for IV thrombolysis within 4.5 h of onset, using only CT for imaging selection. 35 The trial was much larger than previous studies (n ¼ 1100) and reported no difference between treatment arms with respect to either safety or efficacy. Interpretation of NORTEST is complicated by the predominance of very mild stroke patients (median NIHSS at baseline 4), high proportions of TIAs (7%) and stroke mimics (17%), and a high rate of protocol deviations (12%). EXTEND-IA TNK 36 compared 0.25 mg/kg tenecteplase versus 0.9 mg/kg alteplase in ischemic stroke patients with large vessel occlusion planned for thrombectomy. The primary outcome was substantial reperfusion of >50% of the involved territory by the time of the initial angiogram (which occurred at median 55 min after thrombolysis was commenced). This technical efficacy endpoint was chosen, as the thrombectomy procedure was felt to be likely to obscure any potential clinical benefit of tenecteplase. The trial aimed to establish non-inferiority of tenecteplase given that the cost and convenience advantages of tenecteplase would justify a change in practice provided it was convincingly similar in efficacy. In the final analysis, tenecteplase achieved superior reperfusion at initial angiogram (in 22% vs. 10% in the alteplase group, p ¼ 0.023, Figure 1 ). The ordinal analysis of modified Rankin scale at 90 days also favored tenecteplase (cOR 1.7, 95% CI 1.0-2.8, p ¼ 0.037, Figure 2 ). International Journal of Stroke, 13 (9) The difference between tenecteplase and alteplase was largely observed in patients with MCA occlusion and very few patients with ICA occlusion recanalized prior to angiography in either group. Key features of the completed tenecteplase studies are included in Table 1 .
Benefits of using imaging for selection of patients
The trials of tenecteplase have used various approaches to imaging selection. Haley et al. 32 and NORTEST used non-contrast CT only. ATTEST acquired CT perfusion but did not use it for selection into the trial. TEMPO-1 33 and EXTEND-IA TNK 36 required vessel occlusion. TASTE 28 required dual target vessel occlusion and CT perfusion mismatch.
These differences in selection may explain some of the variation in results. While there was no clear benefit of tenecteplase in the overall ATTEST study, exploratory pooled individual patient data meta-analysis of the TASTE and ATTEST studies found that, while there was no significant overall interaction of imaging features with thrombolytic treatment group, patients with independently assessed vessel occlusion had improved recanalization (71% vs. 43%, p < 0.0001, Figure 1 ), which translated into improved clinical outcomes (mRS 0-1 OR 4.82, 95% CI 1.02-7.84, p ¼ 0.05, Figure 2 ) with tenecteplase versus alteplase. 37 Similarly, the group with target mismatch on CT perfusion had improved outcomes with tenecteplase versus alteplase (mRS 0-1 53% vs. 24%, OR 2.33, 95% CI 1.13-5.94; p ¼ 0.032). 40 An additional finding in the target mismatch group treated with tenecteplase was reduced parenchymal hematoma compared to alteplase-treated mismatch patients. These findings are consistent with pooled analyses of desmoteplase trials. Overall, desmoteplase did not show benefit over placebo for thrombolysis beyond 3 h. However, in post hoc analyses, the subgroup with vessel occlusion showed an increase in recanalization and improved outcomes with desmoteplase. 41 Similarly, patients with a large mismatch using perfusion-diffusion MRI showed treatment benefit with desmoteplase. 42 While there was no significant interaction of angiographic variables with treatment effect of alteplase given within 6 h of stroke onset in the angiographic substudy of IST-3, the point estimates for treatment effect in patients without vessel occlusion were notably discordant with the estimates for treatment in those with occlusion: combining IST-3 with other alteplase and desmoteplase trials, there was a significant interaction between the presence of arterial occlusion and treatment effect (p ¼ 0.017). 43 In studies using tenecteplase, alteplase, or desmoteplase, functional outcome among patients without vessel occlusion or mismatch was generally very good in both active and comparator groups, which dilutes the overall treatment effect observed and thus requires larger sample sizes. 44 The benefits of selection by vessel occlusion and/or mismatch can be illustrated by contrasting NORTEST and TEMPO-1, both of which enrolled less severely affected patients but only TEMPO-1 required vessel occlusion, and showed improved outcomes when tenecteplase achieved reperfusion. 33 Large datasets of alteplase-treated patients RCT: randomized-controlled trial; Obs: observational study.
International Journal of Stroke, 13 (9) with multimodal CT before treatment also suggest lack of demonstrable benefit when there is a small perfusion lesion (<15 mL) without occlusion when compared with similar untreated controls. 45 The ongoing trials TEMPO-2 (NCT02398656) and EXTEND-IA TNK II (NCT03340493) have continued to require vessel occlusion and TASTE (ACTRN12613000243718) requires CTP mismatch. The ATTEST-2 (NCT02814409) and TWIST (NCT03181360) trials do not require vessel occlusion, but both are collecting data on vessel occlusion status in subgroups. Key features of these ongoing RCTs are shown in Table 2 .
Ongoing trials of tenecteplase Tenecteplase versus alteplase in disabling stroke: ATTEST-2
The evidence base to date supports the hypotheses of potential improvements in both safety and efficacy of tenecteplase over alteplase, but does not provide conclusive evidence for either superiority or noninferiority. That there are likely to be larger treatment effect sizes among those with imaging-defined therapeutic targets such as large vessel occlusion or substantial volumes of salvageable tissue is expected. 44 Nonetheless, there are potentially important gains if efficacy could be established in a general thrombolysis-eligible population (under 4.5 h, disabling deficit, standard guideline based inclusion/ exclusion criteria) based solely on universally available, simple imaging. Such a study requires a larger sample size than trials that select populations with imaging targets. The ongoing ATTEST-2 study therefore aims to recruit 1870 subjects based on CT and clinical criteria alone and compares tenecteplase 0.25 mg/kg with alteplase 0.9 mg/kg. Results are expected in around two years.
Tenecteplase versus alteplase in patients with penumbra: TASTE trial
The TASTE trial is enrolling acute stroke patients who are clinically eligible for IV thrombolysis, but who also fulfil target mismatch criteria on perfusion CT and using automated software to calculate lesion volumes (ischemic core < 70 mL, penumbral > 15 mL, mismatch ratio > 1.8). The primary outcome is non-inferiority of tenecteplase to alteplase for proportions of patients with mRS 0-1 at 90 days. The calculated sample size is 400 patients, with an interim at 300 patients which will allow for sample size recalculation.
Testing different doses of tenecteplase before thrombectomy for large vessel occlusion: The EXTEND-IA TNK II trial EXTEND-IA TNK II (NCT03340493) is now underway comparing the 0.25 mg/kg dose versus 0.40 mg/kg in patients with large vessel occlusion (ICA, MCA or basilar artery) who are planned for endovascular thrombectomy. The inclusion criteria are broad with no age, clinical severity, or ischemic core restrictions and inclusion of patients with a degree of pre-stroke disability (mRS 3). The primary outcome is substantial reperfusion (>50% of the involved territory i.e. mTICI 2b/3) or no retrievable thrombus at the initial angiographic assessment. Given the greater clot burden, large vessel occlusion patients may have the most to gain from a higher dose of tenecteplase.
Tenecteplase versus non thrombolytic control for wake-up stroke: TWIST About one in five strokes occur during sleep, 46 but patients who have new stroke symptoms when they wake up from sleep (''wake-up stroke'') are currently International Journal of Stroke, 13 (9) excluded from thrombolytic treatment, because the time of stroke onset is unknown. Several studies have shown that the onset of stroke during sleep is close to awakening, 47 and that patients with wake-up stroke share many clinical and radiological findings with patients with stroke duration less than 4.5 h. 48, 49 The bolus administration and the very rapid onset of action make tenecteplase a particularly attractive option for patients with wake-up stroke. The Tenecteplase in Wake-up Ischemic Stroke Trial (TWIST) therefore aims to randomize 500 patients with wake-up stroke to tenecteplase 0.25 mg/kg versus non-thrombolytic standard of care (NCT03181360). Inclusion is not based on imaging criteria, but CT angiography is performed before inclusion and CT perfusion is performed as part of a sub-study.
Tenecteplase versus non thrombolytic control for minor stroke with intracranial artery occlusion: TEMPO-2 trial
In minor stroke, where the balance between safety and efficacy is even more critical, tenecteplase may be a pharmacologically superior agent. The TEMPO-2 trial is randomizing 1274 minor stroke patients with intracranial occlusion to tenecteplase 0.25 mg/kg versus nonthrombolytic standard of care (NCT02398656). To be included, patients need to be assessed as non-disabling based on their presenting deficits (NIHSS 0-5). Patients need to treat within 12 h of onset and within 90 min of the CT/CTA. Patients will be included if they have a premorbid mRS of 0-2. Primary outcome is a responder analysis at 90 days with 0-1 being a good outcome in patients with a pre-morbid mRS of 0.1 and 2 being a good outcome in patients with a pre-morbid mRS of 2.
Conclusions
Tenecteplase shows promise for the treatment of all types of acute ischemic stroke. From a practical point of view, tenecteplase is easier to use, as it is quickly administered as a single bolus. Emerging data suggest that tenecteplase has higher recanalization rates and is at least as safe as alteplase. Trials are ongoing that are comparing tenecteplase with alteplase, and testing tenecteplase in subgroups of patients with ischemic stroke. Thrombolytic treatment will continue to be a key part of the treatment of acute stroke worldwide and using a better thrombolytic such as tenecteplase will have a global impact.
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